136232-82-1

Basic information

• Product Name: buprenorphine
• Synonyms: 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, [5β,6β,7β(R),9α,13α,14β]-
• CAS NO: 136232-82-1
• Molecular Formula: C₂₉H₄₁NO₄
• Molecular Weight: 467.65
• Mol File: 136232-82-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: buprenorphine(CAS DataBase Reference)
• NIST Chemistry Reference: buprenorphine(136232-82-1)
• EPA Substance Registry System: buprenorphine(136232-82-1)

Safety Data

• Hazardous Substances Data: 136232-82-1(Hazardous Substances Data)

Upstream product

• 1160847-07-3 C₂₅H₃₁NO₄ 
• 594-19-4 tert.-butyl lithium 

Related news

Short CommunicationPerceived need and availability of psychosocial interventions across buprenorphine (cas 136232-82-1) prescriber specialties09/07/2019

IntroductionPsychosocial interventions are often recommended as part of buprenorphine treatment for patients with opioid use disorder, but little is known about prescriber perspectives on their use and how this varies across buprenorphine prescriber specialties.detailed

Epidemiology of severe buprenorphine (cas 136232-82-1) exposures reported to the U.S. Poison Centers09/06/2019

ObjectiveThis study aims to evaluate the trends and risk factors of severe buprenorphine outcomes (SBO) reported to the U.S. Poison Centers (PCs).detailed

A comparison of buprenorphine (cas 136232-82-1) and psychosocial treatment outcomes in psychosocial and medical settings09/05/2019

BackgroundFacing an epidemic of opioid-related mortality, many government health departments, insurers, and treatment providers have attempted to expand patient access to buprenorphine in psychosocial substance use disorder (SUD) programs and medical settings.detailed

Review articleTransdermal buprenorphine (cas 136232-82-1) patch: Potential for role in management of opioid dependence09/04/2019

Despite proven clinical utility, use of sublinugual buprenorphine is fraught with issues of potential diversion among patients with opioid dependence. Transdermal buprenorphine patches provide an alternative delivery model that can be utilized to reduce such diversion. This narrative review disc...detailed

Research Paper“They're making it so hard for people to get help:” Motivations for non-prescribed buprenorphine (cas 136232-82-1) use in a time of treatment expansion09/03/2019

BackgroundBuprenorphine maintenance therapy (BMT) has been widely recognized as one of the most effective treatments for opioid use disorders (OUD). In the midst of the U.S. opioid overdose crisis, local, state, and federal authorities have attempted to increase the availability of BMT, yet few ...detailed

Evaluation of an emergency department buprenorphine (cas 136232-82-1) induction and medication-assisted treatment referral program09/02/2019

BackgroundEmergency departments are struggling to manage the increasing number of patients seen for opioid use disorders and opioid overdose. With opioid overdose deaths rising at alarming rates, emergency physicians are beginning to induce patients with long-acting opioids such as buprenorphine...detailed

Effects of ascending buprenorphine (cas 136232-82-1) doses on measures of experimental pain: A pilot study08/31/2019

BackgroundBuprenorphine is widely used in the treatment of opioid use disorder and pain management. Little is known about the analgesic effects of high-dose sublingual buprenorphine, particularly in doses of >8 mg. The aim of this study was to examine the effect of ascending doses of buprenorphi...detailed

buprenorphine (cas 136232-82-1) in the United States: Motives for abuse, misuse, and diversion08/30/2019

Opioid use disorder (OUD) and its consequences are a major public health concern. The partial agonist buprenorphine is a safe and effective treatment for OUD, but concerns about abuse, misuse, and diversion of buprenorphine have been raised. This narrative review examined the rates and motives f...detailed

Full length articleMaternal buprenorphine (cas 136232-82-1) treatment during pregnancy and maternal physiology08/29/2019

BackgroundBuprenorphine, used for opioid use disorder (OUD) treatment during pregnancy, provides unknown effects on maternal physiological activity. The primary aim of this report is to document acute effects of buprenorphine administration on indicators of maternal autonomic functioning. Effect...detailed

Relevant articles and documents

Process for the preparation of buprenorphine and derivatives for buprenorphine

The invention generally provides processes for the production of buprenophine and derivatives of buprenorphine. In particular, the process may encompass synthetic routes for the production of buprenorphine or derivatives of buprenorphine from norhydromorp